Catheterization Lab Equipment in Minnesota

Stereotaxis is a pioneer in endovascular robotics and robotic-assisted interventional medicine. The company develops and commercializes robotic systems designed to enhance precision and control in minimally invasive cardiovascular and other interventional procedures. Their primary focus is cardiac ablation therapy, where robotic-assisted navigation enables physicians to perform complex catheter-based treatments with improved safety and efficacy. The company markets solutions to interventional cardiologists, electrophysiologists, and hospital systems, positioning robotic assistance as an alternative to traditional manual catheterization. Stereotaxis operates a B2B model directed at hospital networks and interventional centers, with clinical data and peer-reviewed evidence supporting their technology. The company also offers telemedicine-enabled robotic capabilities (TeleRobotics), expanding procedural access geographically. Products are marketed through direct sales to hospitals and physician networks, with clinical training and support provided to end users.

Scanlan International, Inc. is a family-owned manufacturer of precision handcrafted surgical instruments established in 1921 and based in Saint Paul, Minnesota. Operating in their fourth generation, the company specializes in cardiovascular, microsurgical, minimally invasive, and temporary occlusion surgical instruments. Scanlan manufactures reusable and single-use surgical instruments including forceps, needle holders, scissors, clamps, retractors, suction instruments, and specialized tools for VATS/MIS procedures. The company is renowned for its proprietary products such as VASCU-STATT® bulldog clamps, Reliance Bulldog clamps, and the SCANTURIAN® minimally invasive surgical instrument line. All instruments are handcrafted using premium medical-grade stainless steel and titanium with advanced coatings for enhanced durability and performance. Scanlan offers comprehensive support services including instrument restoration, modification, cleaning and sterilization guidance, warranty coverage, and custom modifications. The company collaborates closely with surgeons across specialties to design and refine instruments for evolving procedural needs, serving hospital operating rooms and surgical teams globally.

Seigla Medical manufactures the liquID® Guide Catheter Extension, a specialized interventional cardiology device designed for percutaneous coronary intervention (PCI) procedures. The product features an 18% larger lumen and 45% thinner wall (0.0030″ vs. 0.0050″) compared to conventional guide catheters, enabling physicians to navigate complex coronary anatomy with improved access and reduced trauma. The liquID® is available in radial-access-compatible 6Fr and 7Fr configurations, supporting both femoral and radial vascular access approaches without requiring access conversion. The company holds ISO 13485:2016 certification under the MDSAP framework and maintains CE marking in Europe. Products are distributed internationally through a global network of medical device distributors. Seigla Medical serves interventional cardiologists and cardiac catheterization laboratories in both US and international markets.

VitalPath is a specialized medical device contract manufacturer and design services provider focused on complex catheter systems and precision laser components for cardiovascular, neurovascular, and endoscopy applications. The company operates three ISO 13485:2016-certified manufacturing facilities in Minnesota: New Hope (28,000 sq ft R&D design center with 4,200 sq ft ISO 7 cleanroom), Maplewood (12,000 sq ft catheter development and manufacturing with 7,000 sq ft ISO 7 cleanroom), and Cokato (36,000 sq ft precision laser and sub-assembly facility with 12,500 sq ft ISO 7 cleanroom). VitalPath serves as a full-service partner across the product development lifecycle, from feasibility and rapid prototyping through design, engineering, manufacturing validation, and commercialization. Core competencies include steerable catheters, balloon catheters, ablation catheters, microcatheters, aspiration catheters, thrombectomy catheters, energy-delivery devices, and transseptal delivery systems. Primary markets include electrophysiology (mapping, ablation, transseptal), structural heart (TAVR, TTVR, TMVR, LAA delivery), neurovascular (embolization, thrombectomy), coronary/peripheral vascular (stent delivery, PTA), and endoscopy applications. The company emphasizes rapid prototyping, responsive engineering, and flexible product development processes tailored to customer stage and needs. FDA registration confirmed at Cokato facility.

Imricor Medical Systems is a US-based medical device manufacturer specializing in MRI-compatible ablation and diagnostic catheters for interventional cardiac magnetic resonance (iCMR) procedures. Founded in 2006 and headquartered in Burnsville, Minnesota, the company pioneered safe MRI-guided cardiac catheter ablation technology. The company's flagship product, the Vision-MR Ablation Catheter 2.0, operates under real-time MRI guidance to treat cardiac arrhythmias, particularly ventricular tachycardia, with improved safety and efficiency compared to traditional X-ray fluoroscopy methods. Imricor's product portfolio also includes the Vision-MR Diagnostic Catheter, Advantage-MR EP Recorder/Stimulator for electrophysiology recording and cardiac stimulation, and the NorthStar Mapping System for cardiac substrate visualization and ablation guidance within the MRI environment. The company holds CE Mark approval in Europe and has recently obtained FDA clearance in the United States. Imricor serves approximately 15 European sites and has established partnerships including a sales agreement with Philips for broader market distribution.

Kardium Inc. designs and manufactures the Globe® Pulsed Field System, an advanced cardiac ablation platform for the treatment of atrial fibrillation. The Globe System is an all-in-one catheter-based solution that integrates high-density electrophysiological mapping with pulsed field ablation therapy, enabling patient-specific treatment delivery. The system features 122 individually selectable electrodes that allow precise electrode customization for each patient's cardiac anatomy and arrhythmia substrate. The platform consolidates mapping and ablation capabilities into a single catheter, streamlining interventional electrophysiology workflows and reducing procedure complexity. Kardium targets hospital electrophysiology laboratories and cardiac catheterization centers managing patients with atrial fibrillation and related arrhythmias. The company positions the Globe System as a differentiated approach to catheter-based cardiac ablation, emphasizing precision therapy delivery, high-density mapping resolution, and workflow efficiency. The technology is designed for use by interventional cardiologists and electrophysiologists in hospital-based and outpatient EP labs.

Midwest Interventional Systems (MIS) is a vertically integrated, FDA-registered medical device contract manufacturer and design partner specializing in catheter systems and minimally invasive device components. The company designs and manufactures custom medical balloons (non-compliant, semi-compliant, and compliant variants) and medical extrusions (single-lumen to complex multilumen tubing) for interventional and endovascular applications. MIS serves 100+ minimally invasive device companies spanning neurovascular, atrial fibrillation, endoscopy, and other specialties. The company operates three core business units: Components (off-the-shelf and custom balloons and extrusions via online design tools), Design Services (concept-to-commercialization catheter engineering with a dedicated Co-Lab for rapid prototyping), and Manufacturing (pilot through full-scale contract manufacturing with in-house capabilities). Key offerings include IQueue (proprietary online extrusion designer for rapid custom ordering), Balloon Designer, Catheter Designer, and an online component store with 24-hour shipping and $50 minimum orders. MIS maintains ISO 14385:2016 certification and FDA registration. The company employs catheter engineers with 10+ decades of combined expertise and follows a proven 5-phase development methodology. Notable clients and testimonials reference work with neurovascular innovators, endoscope manufacturers, atrial fibrillation device companies, Mayo Clinic physician innovators, and leading MedTech firms.

Resolution Medical is a medical device development and manufacturing partner specializing in complex catheter delivery systems, active implantable devices, and component manufacturing. The company serves structural heart, cardiology, vascular, heart failure (VAD), neuromodulation, electrophysiology, and additional specialty markets including ENT, neurology, urology, oncology, endoscopy, and robotics. Core capabilities span the full product lifecycle: concept and design development, BioSimulation and testing with cardiovascular visualization in pressurized heart models, New Product Introduction (NPI) with design-for-manufacturing optimization, and end-to-end manufacturing from prototyping through commercial production. Resolution Medical operates specialized clean rooms, sterile packaging, labeling, and distribution infrastructure. In structural heart, the company develops implants and catheter delivery systems for mitral, tricuspid, aortic, and pulmonary valve interventions, as well as shunts, stents, closure devices, and embolic protection. Cardiology and vascular expertise includes complex delivery platforms, imaging and sensing catheter systems for peripheral, neurovascular, and cardiovascular applications, DVT/PE management, drug delivery, and flow management. Heart failure capabilities encompass VAD pump development, drivelines, and deployment systems. Neuromodulation focus includes Class III active implantables: implantable pulse generators (IPGs), leads, headers, adapters, and subassemblies for spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, and peripheral nerve modulation. Electrophysiology specialization covers diagnostic mapping and energy delivery catheters with modalities including pulsed field ablation (PFA), RF energy, cryotherapy, and vapor therapy. The company maintains a quality management system per ISO 13485:2016 and operates under FDA guidelines. Resolution Medical was recently acquired by Resonetics (2025) and operates with 100+ engineers backed by 1,000+ combined years of experience.

Technical Services for Electronics (TSE), operating as a brand of AMETEK Paragon Medical, is a custom medical device component manufacturer specializing in precision interconnect solutions, cable assemblies, and laser-processed components for leading medical device OEMs. The company provides collaborative engineering and advanced manufacturing capabilities across 40+ years of medical device innovation, serving electrophysiology, neuromodulation, cardiac rhythm management, patient monitoring, vascular, surgical instruments, orthopedic, and structural heart device markets. TSE manufactures components from specialty materials including Nitinol, PEEK, stainless steel, and silicone. Core offerings include custom electrical interconnects, DENSYTY interconnect systems, cable assemblies with smart PCB integration, laser ablation of polymers, fine wire components, catheter manufacturing, Nitinol laser processing, precision tube cutting, laser welding, and laser hole drilling. The company operates as part of AMETEK Inc.'s Paragon Medical division alongside brands Avicenna and Laserage. TSE provides world-class manufacturing with robust quality systems and integrative service models designed to accelerate time-to-market for innovative medical device concepts across multiple clinical specialties.

HistoSonics, Inc. is a medical device manufacturer specializing in histotripsy, a proprietary non-invasive ultrasound technology that mechanically destroys targeted tissue without surgery, heat, or incisions. Founded in 2009 by University of Michigan experts, the company has developed the Edison system—an FDA-approved, robotic, image-guided platform for the non-invasive mechanical destruction of liver tumors. The Edison system uses focused ultrasound to create a controlled bubble cloud that liquefies unwanted tissue in real-time at the sub-cellular level. With over 100 systems deployed globally and significant insurance coverage expansion (7 million BCBS Highmark members), HistoSonics is actively expanding clinical applications beyond liver oncology to kidneys and pancreas through ongoing HOPE4KIDNEY and GANNON clinical trials. The company serves interventional radiologists, surgical oncologists, hepatologists, and transplant surgeons, positioning histotripsy as a tissue-sparing alternative to traditional surgical and thermal ablation approaches for tumor treatment.

AtriCure, Inc. is a medical device manufacturer specializing in surgical solutions for atrial fibrillation (Afib) management and post-operative pain management. The company's primary product portfolio centers on left atrial appendage (LAA) exclusion and surgical ablation devices. The AtriClip device family represents the company's flagship offering, with over 750,000 procedures performed worldwide and 672,000 devices sold globally. AtriClip variants include AtriClip FLEX-Mini, AtriClip Mini, and EnCompass, designed to support diverse surgical approaches from minimally invasive procedures to complex anatomies. The BoxX surgical ablation system enables comprehensive Afib treatment during cardiac procedures such as coronary artery bypass grafting (CABG). AtriCure also offers Hybrid AF Therapy, combining percutaneous and surgical approaches for long-standing persistent Afib patients. Additionally, the company manufactures cryoICE and cryoXT technologies for cryo nerve block procedures, providing non-opioid post-amputation pain management solutions. Clinical evidence supporting the product portfolio includes over 100 published studies demonstrating 100% LAA closure rates with zero leaks and zero serious adverse events at 30 days. The company serves cardiac surgeons, electrophysiologists, and general cardiologists across hospital and surgical center settings globally. Products are designed for use in operating rooms and cardiac catheterization laboratories.

Nordson Corporation is a global precision technology manufacturer founded in 1954, headquartered in Westlake, Ohio, with operations in 35+ countries. The company serves diverse end markets including medical, pharmaceutical, and life science industries through eleven specialized divisions. Nordson Medical manufactures medical equipment including custom tubing, balloons, catheters, syringe barrels and cartridges, biomaterial delivery devices, and fluid management components for medical device manufacturers. The company designs and manufactures fully-integrated systems, after-market parts, and consumables for critical medical applications. Nordson EFD provides engineered fluid dispensing equipment and single-use components used in medical device assembly. Products include dispense tips, needles, and precision fluid delivery systems. The company serves regulatory-intensive markets and delivers manufacturing solutions for medical device OEMs requiring precision engineering, quality control, and compliance with medical device standards. Nordson's capabilities span equipment manufacturing, custom component fabrication, fluid management systems, and precision dispensing technologies essential to medical device production and delivery systems.

Minnesota MedTec is an FDA-registered, ISO 13485:2003-certified contract manufacturer specializing in precision medical device components and subassemblies. The company provides comprehensive outsourcing services including extrusion, molding, tube processing, and product assembly for interventional cardiology, radiology, neuroradiology, urology, and gastroenterology applications. Core capabilities encompass custom medical tubing, balloons, braided delivery systems, catheters, and molded polymer components manufactured from medical-grade resins. The company serves as a full-service partner from concept through commercialization, offering clean-room assembly, quality assurance, and regulatory compliance expertise. Minnesota MedTec's manufacturing processes include precision extrusion, injection molding, ultrasound tip forming, multi-durometer shafts, and specialized tube processing techniques to support minimally invasive medical device production.

QXMedical designs and manufactures first-in-class medical devices for minimally invasive coronary, peripheral, and endovascular interventions. The company specializes in proprietary balloon and delivery catheter platforms for three primary clinical applications: endovascular interventions (catheters and embolic agents for vascular disease and embolization therapy); coronary and peripheral vascular interventions (catheters for treatment of coronary and peripheral artery disease); and emergency and trauma care (minimally invasive catheter options for hemorrhage control, including REBOA—Resuscitative Endovascular Balloon Occlusion of the Aorta—and SVC tear management). QXMedical positions itself as a technology-driven manufacturer offering high-performance devices built on proprietary technology platforms emphasizing quality and clinical effectiveness. The company operates a strategic partnership program, indicating a B2B model serving interventional cardiology, vascular surgery, and trauma/emergency medicine markets. No specific FDA clearances, ISO certifications, or 510(k) information is listed on the fetched content.

Nextern Innovation is a vertically integrated medical device contract design, development, and manufacturing organization (CDMO). The company collaborates with innovators and clinicians to design, develop, optimize, and manufacture medical devices across multiple therapeutic areas. Nextern operates four global manufacturing facilities totaling 250,000 square feet, including 20,000 square feet of cleanroom space, with a team of 600+ members worldwide. The company specializes in minimally invasive devices, single-use catheter and metal assemblies, Class III active implantable leads and delivery systems, power systems (catheter and generator development), bioelectronics, and connected care solutions. Nextern Liink, a subsidiary, develops custom, secure, and scalable software solutions for medical device connectivity. Core capabilities include device design and development (bio-simulation, pre-clinical testing, IP support), full-spectrum manufacturing with phased transition from development to commercialization, supply chain management, and life-cycle services including warranty and continuous improvement. The company operates virtual quality management systems and maintains presence in strategically located global manufacturing locations with localized supply chains. Nextern serves cardiology, neuromodulation, and other specialty device markets, with demonstrated expertise in brain-computer interfaces and platforms for labeling and graphical user interfaces.

InSitu Technologies Inc. is a privately held medical device company specializing in intra-vascular stents and cardiovascular products for coronary and peripheral intervention. The company manufactures a portfolio of covered stents, drug-eluting stents, and drug-coated balloons designed for minimally invasive vascular intervention. Product lines include: Celosia™ Covered Stent for treatment of free coronary perforations in native vessels ≥2.25mm diameter; Silene™ Covered Stent for peripheral vascular applications; Siro™ Drug Eluting Stent utilizing sirolimus coating and patented Direct-Stent® design to reduce restenosis; Kauree™ Covered Stent (coming soon) for tracheobronchial strictures caused by malignant neoplasms; and AaRiss™ Drug Coated Balloon for coronary and peripheral use. The company reports 25+ years of operational history with distribution spanning over 40 countries across six continents, 219,470+ stents implanted, and 190,560+ PTCA balloon catheters deployed. InSitu emphasizes physician collaboration in product design and maintains in-house capabilities for design, development, manufacturing, and licensing. The company participates in major international cardiology conferences including EuroPCR. Regulatory status and specific FDA clearances are not detailed in available content.

LightningCath is an ISO 13485-certified medical device manufacturer specializing in the design, prototyping, and manufacturing of high-quality catheter systems and components for minimally invasive procedures. Based in Brooklyn Park, Minnesota, the company operates an ISO 7 cleanroom facility and emphasizes rapid turnaround times to serve smaller medical device companies and healthcare professionals. LightningCath offers comprehensive catheter manufacturing services including design and prototyping, extrusion (single and multi-lumen thermoplastic and fluoropolymer tubing), injection molding, electrode assembly, and value-added services such as shape setting, tipping, micro-molding, crimping, and balloon bonding. The company supports applications across intravenous therapy, neurovascular interventions, and structural heart procedures, with capabilities ranging from low-to-high volume production and quick-turn development cycles.

EGG Medical, Inc. manufactures integrated radiation protection systems for interventional fluoroscopy and cardiac catheterization laboratories. The company's flagship product, EggNest System, is a full-room radiation shielding solution designed to reduce occupational radiation exposure for all staff members in the procedure room—physicians, nurses, technicians, and support personnel—by 360-degree integrated protection positioned at the head of the table, above, and below. The system enables staff to work with ultralight or no lead aprons, significantly reducing musculoskeletal strain and improving workflow efficiency. EggNest is optimized for existing interventional lab workflows and complies with emerging ALARA+ standards for occupational radiation protection. The company's technology is supported by peer-reviewed clinical evidence published in cardiology and interventional radiology journals, including studies in the Journal of the American College of Cardiology and the Journal of the Society for Cardiovascular Angiography and Interventions. EggNest is FDA-cleared and designed for cardiac catheterization labs, vascular intervention suites, and other fluoroscopy-dependent procedure rooms. The company serves hospitals and health systems performing coronary interventions, peripheral vascular procedures, and other image-guided interventions.

Surmodics, Inc. is a specialized medical device company focused on three core business segments: interventional endovascular products, performance coatings for intravascular medical devices, and in vitro diagnostic (IVD) chemical components. The company is a global leader in customized hydrophilic, hemocompatible, and drug-delivery surface coatings applied to complex intravascular devices for interventional cardiology, neurovascular, and peripheral vascular procedures. Surmodics manufactures and markets breakthrough endovascular thrombectomy and vascular access platforms, including the Pounce™ Thrombectomy Platform (for arterial and venous thrombi in vessels 2–16mm diameter range), Pounce™ Venous Thrombectomy System, and Sublime™ Radial Access Platform for radial-to-peripheral interventions. The company also provides Preside™ Hydrophilic Coatings for neuro, coronary, and peripheral device applications. As a Contract Development and Manufacturing Organization (CDMO), Surmodics offers end-to-end development and scalable manufacturing services for complex medical devices. In the IVD space, Surmodics supplies high-performance chemical components for immunoassay tests and microarray diagnostics, enabling signal amplification and noise reduction in diagnostic platforms. The company operates under FDA regulation, with products restricted to physician sale and use. Surmodics serves interventional radiologists, cardiologists, vascular surgeons, and diagnostic test manufacturers globally.

Chitogen Inc manufactures next-generation hemostatic products utilizing proprietary chitosan fiber technology to accelerate natural blood clot formation. The company's flagship product, the SoftSeal-STF (Surface Treated Fiber) Hemostatic Pad, is FDA-approved and designed for rapid hemostasis with improved patient comfort and reduced compression time. Chitogen products serve surgical, cardiovascular catheterization, and dialysis environments, offering patented technology that demonstrates proven improvement in time to hemostasis. The product line combines clinical efficacy with superior staff and patient satisfaction, addressing critical bleeding control needs across multiple clinical settings. The company emphasizes safety, speed, and ease of use in perioperative and interventional care applications.

Cardio Flow, Inc. is a medical device manufacturer specializing in orbital atherectomy systems for the treatment of peripheral artery disease (PAD). The company's flagship product, FreedomFlow, is a modern atherectomy platform featuring diamond-coated rotating spheres designed to efficiently treat complex vascular lesions across a wide range of vessel diameters (2 mm to 8 mm). The platform offers multiple catheter configurations (5 Fr and 6 Fr variants with 3- or 5-sphere driveshafts), adjustable rotational speeds (50K–76K RPM), and single-device versatility for treating multiple blockages and vessel types from ankle to hip. FreedomFlow is designed for use in hospital operating rooms, ambulatory surgery centers, and office-based interventional labs, emphasizing workflow optimization, reduced capital costs, minimal inventory requirements, and rapid physician adoption with a shallow learning curve.

NeoChord, Inc. is a privately held medical technology company specializing in beating heart mitral valve repair. The company manufactures the NeoChord Artificial Chordae Delivery System (Model DS1000), an echo-guided, minimally invasive treatment for patients with mitral valve regurgitation. The device enables direct repair of the mitral valve on a beating heart without requiring cardiopulmonary bypass, preserving the valve structure and future treatment options. The system uses artificial chords deployed via transapical access under echocardiographic guidance. NeoChord's technology improves procedural control, restores mitral valve function, and has been evaluated in multiple clinical studies across numerous countries. The company holds CE marking conformity under European Medical Device Regulation (MDR) 2017/745. In the United States, the device is investigational and limited to investigational use by federal law. NeoChord serves cardiac surgeons, interventional cardiologists, and cardiac care centers treating mitral valve disease. The company maintains a focus on clinical evidence generation, with multiple peer-reviewed publications documenting feasibility, safety, and efficacy of the procedure, including novel applications such as re-repair and use in complex anatomies.